Nls pharmaceutics ltd. and kadimastem ltd.

The proposed transaction will create a nasdaq-traded, biotechnology company with product candidates in advanced stages of clinical development and a focus on advancing its allogeneic cell therapy platform zurich and ness ziona, israel , dec. 30, 2024 /prnewswire/ -- nls pharmaceutics ltd. ("nls") (nasdaq: nlsp), a swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, and kadimastem ltd.
NLSP Ratings Summary
NLSP Quant Ranking